Treatment of older patients with mantle-cell lymphoma

H C Kluin-Nelemans; E Hoster; O Hermine; J Walewski; M Trneny; C H Geisler; S Stilgenbauer; C Thieblemont; U Vehling-Kaiser; J K Doorduijn; B Coiffier; R Forstpointner; H Tilly; L Kanz; P Feugier; M Szymczyk; M Hallek; S Kremers; G Lepeu; L Sanhes; J M Zijlstra; R Bouabdallah; P J Lugtenburg; M Macro; M Pfreundschuh; V Procházka; F Di Raimondo; V Ribrag; M Uppenkamp; M André; W Klapper; W Hiddemann; M Unterhalt; M H Dreyling

doi:10.1056/NEJMoa1200920

Treatment of older patients with mantle-cell lymphoma

H C Kluin-Nelemans, E Hoster, O Hermine, J Walewski, M Trneny, C H Geisler, S Stilgenbauer, C Thieblemont, U Vehling-Kaiser, J K Doorduijn, B Coiffier, R Forstpointner, H Tilly, L Kanz, P Feugier, M Szymczyk, M Hallek, S Kremers, G Lepeu, L SanhesJ M Zijlstra, R Bouabdallah, P J Lugtenburg, M Macro, M Pfreundschuh, V Procházka, F Di Raimondo, V Ribrag, M Uppenkamp, M André, W Klapper, W Hiddemann, M Unterhalt, M H Dreyling

469 Citations (Scopus)

Abstract

The long-term prognosis for older patients with mantle-cell lymphoma is poor. Chemoimmunotherapy results in low rates of complete remission, and most patients have a relapse. We investigated whether a fludarabine-containing induction regimen improved the complete-remission rate and whether maintenance therapy with rituximab prolonged remission.

Original language	English
Journal	New England Journal of Medicine
Volume	367
Issue number	6
Pages (from-to)	520-31
Number of pages	12
ISSN	0028-4793
DOIs	https://doi.org/10.1056/NEJMoa1200920
Publication status	Published - 2012

Keywords

Aged
Aged, 80 and over
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Combined Chemotherapy Protocols
Cyclophosphamide
Doxorubicin
Female
Humans
Induction Chemotherapy
Intention to Treat Analysis
Lymphoma, Mantle-Cell
Maintenance Chemotherapy
Male
Middle Aged
Prednisone
Prospective Studies
Remission Induction
Survival Rate
Vidarabine
Vincristine

Access to Document

10.1056/NEJMoa1200920

Cite this

Kluin-Nelemans, H. C., Hoster, E., Hermine, O., Walewski, J., Trneny, M., Geisler, C. H., Stilgenbauer, S., Thieblemont, C., Vehling-Kaiser, U., Doorduijn, J. K., Coiffier, B., Forstpointner, R., Tilly, H., Kanz, L., Feugier, P., Szymczyk, M., Hallek, M., Kremers, S., Lepeu, G., ... Dreyling, M. H. (2012). Treatment of older patients with mantle-cell lymphoma. New England Journal of Medicine, 367(6), 520-31. https://doi.org/10.1056/NEJMoa1200920

Kluin-Nelemans, HC, Hoster, E, Hermine, O, Walewski, J, Trneny, M, Geisler, CH, Stilgenbauer, S, Thieblemont, C, Vehling-Kaiser, U, Doorduijn, JK, Coiffier, B, Forstpointner, R, Tilly, H, Kanz, L, Feugier, P, Szymczyk, M, Hallek, M, Kremers, S, Lepeu, G, Sanhes, L, Zijlstra, JM, Bouabdallah, R, Lugtenburg, PJ, Macro, M, Pfreundschuh, M, Procházka, V, Di Raimondo, F, Ribrag, V, Uppenkamp, M, André, M, Klapper, W, Hiddemann, W, Unterhalt, M & Dreyling, MH 2012, 'Treatment of older patients with mantle-cell lymphoma', New England Journal of Medicine, vol. 367, no. 6, pp. 520-31. https://doi.org/10.1056/NEJMoa1200920

@article{8a78e17bb6564c5ba5d5be0d07eab584,

title = "Treatment of older patients with mantle-cell lymphoma",

abstract = "The long-term prognosis for older patients with mantle-cell lymphoma is poor. Chemoimmunotherapy results in low rates of complete remission, and most patients have a relapse. We investigated whether a fludarabine-containing induction regimen improved the complete-remission rate and whether maintenance therapy with rituximab prolonged remission.",

keywords = "Aged, Aged, 80 and over, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Combined Chemotherapy Protocols, Cyclophosphamide, Doxorubicin, Female, Humans, Induction Chemotherapy, Intention to Treat Analysis, Lymphoma, Mantle-Cell, Maintenance Chemotherapy, Male, Middle Aged, Prednisone, Prospective Studies, Remission Induction, Survival Rate, Vidarabine, Vincristine",

author = "Kluin-Nelemans, \{H C\} and E Hoster and O Hermine and J Walewski and M Trneny and Geisler, \{C H\} and S Stilgenbauer and C Thieblemont and U Vehling-Kaiser and Doorduijn, \{J K\} and B Coiffier and R Forstpointner and H Tilly and L Kanz and P Feugier and M Szymczyk and M Hallek and S Kremers and G Lepeu and L Sanhes and Zijlstra, \{J M\} and R Bouabdallah and Lugtenburg, \{P J\} and M Macro and M Pfreundschuh and V Proch{\'a}zka and \{Di Raimondo\}, F and V Ribrag and M Uppenkamp and M Andr{\'e} and W Klapper and W Hiddemann and M Unterhalt and Dreyling, \{M H\}",

year = "2012",

doi = "10.1056/NEJMoa1200920",

language = "English",

volume = "367",

pages = "520--31",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "6",

}

TY - JOUR

T1 - Treatment of older patients with mantle-cell lymphoma

AU - Kluin-Nelemans, H C

AU - Hoster, E

AU - Hermine, O

AU - Walewski, J

AU - Trneny, M

AU - Geisler, C H

AU - Stilgenbauer, S

AU - Thieblemont, C

AU - Vehling-Kaiser, U

AU - Doorduijn, J K

AU - Coiffier, B

AU - Forstpointner, R

AU - Tilly, H

AU - Kanz, L

AU - Feugier, P

AU - Szymczyk, M

AU - Hallek, M

AU - Kremers, S

AU - Lepeu, G

AU - Sanhes, L

AU - Zijlstra, J M

AU - Bouabdallah, R

AU - Lugtenburg, P J

AU - Macro, M

AU - Pfreundschuh, M

AU - Procházka, V

AU - Di Raimondo, F

AU - Ribrag, V

AU - Uppenkamp, M

AU - André, M

AU - Klapper, W

AU - Hiddemann, W

AU - Unterhalt, M

AU - Dreyling, M H

PY - 2012

Y1 - 2012

N2 - The long-term prognosis for older patients with mantle-cell lymphoma is poor. Chemoimmunotherapy results in low rates of complete remission, and most patients have a relapse. We investigated whether a fludarabine-containing induction regimen improved the complete-remission rate and whether maintenance therapy with rituximab prolonged remission.

AB - The long-term prognosis for older patients with mantle-cell lymphoma is poor. Chemoimmunotherapy results in low rates of complete remission, and most patients have a relapse. We investigated whether a fludarabine-containing induction regimen improved the complete-remission rate and whether maintenance therapy with rituximab prolonged remission.

KW - Aged

KW - Aged, 80 and over

KW - Antibodies, Monoclonal, Murine-Derived

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Cyclophosphamide

KW - Doxorubicin

KW - Female

KW - Humans

KW - Induction Chemotherapy

KW - Intention to Treat Analysis

KW - Lymphoma, Mantle-Cell

KW - Maintenance Chemotherapy

KW - Male

KW - Middle Aged

KW - Prednisone

KW - Prospective Studies

KW - Remission Induction

KW - Survival Rate

KW - Vidarabine

KW - Vincristine

UR - https://www.scopus.com/pages/publications/84864715966

U2 - 10.1056/NEJMoa1200920

DO - 10.1056/NEJMoa1200920

M3 - Journal article

C2 - 22873532

SN - 0028-4793

VL - 367

SP - 520

EP - 531

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 6

ER -

Treatment of older patients with mantle-cell lymphoma

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this